Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

MeSH Review:

Impotence, Vasculogenic

Lin, J.S. et al., Bakircioglu, M.E. et al., Lin, C.S. et al., Rodger, R.S. et al., Kadioğlu, A. et al., et al.

Lin, Lin, Chen, Ho, Lue, Lin, Ho, Chen, Lin, Nunes, Lue,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on Impotence, Vasculogenic

Vasculogenic impotence is the most consistent organic erectile abnormality in RAI [1].
PURPOSE: Because decreased trabecular smooth muscle content is reportedly associated with vasculogenic impotence in men, we performed a rodent study to investigate the effect of aging on trabecular smooth muscle content and caveolin-1 protein expression in penile smooth muscle cells [2].
PURPOSE: We investigated forskolin, a direct adenylate cyclase activator, as an intracavernosal vasoactive agent in management of vasculogenic impotence [3].
For the 13 patients with arteriogenic impotence (group 3) we compared the urinary 11-dehydro-thromboxane B2 and prostaglandin F1 alpha levels before and after intracavernous injection of prostaglandin E1 by using a paired t test [4].
The mean urinary 11-dehydro-thromboxane B2 level of 3 patients with arteriogenic impotence was significantly greater than that of the 57 control volunteers: 2.66 +/- 0.65 versus 1.74 +/- 0.56 (plus or minus standard deviation) ng./mg. creatinine (p = 0.008) [4].

Chemical compound and disease context of Impotence, Vasculogenic

Our findings show that cavernosometry after intracavernous injection of papaverine will provide more valuable information in patients in whom venogenic impotence is suspected [5].
Intracavernous injection of prostaglandin E1 was used in 210 men as a screening test for the differential diagnosis of vasculogenic impotence [6].
The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence [4].
Prostacyclin-to-thromboxane A2 ratio in arteriogenic impotence [7].
To explore the possibility of using venous sclerosant therapy to overcome venogenic impotence we studied the effects of ethanolamine on the veins draining the dog penis [8].

Biological context of Impotence, Vasculogenic

Although follicle-stimulating hormone levels were higher (p = 0.001) and penile blood pressure index levels lower (p less than 0.05) in patients with impotence, sexual function was not improved by exogenous testosterone, and vasculogenic impotence was identified in only 6% of patients [9].

Gene context of Impotence, Vasculogenic

We have previously shown that intracavernous injection of vascular endothelial growth factor (VEGF) improved the recovery of erectile function in an arteriogenic impotence rat mode [10].
OBJECTIVE: To identify genes that are affected by vascular endothelial growth factor (VEGF), as an intracavernosal injection with VEGF improved the recovery of erectile function in a rat model of arteriogenic impotence, specifically examining the three nitric oxide synthase (NOS) genes, nNOS, eNOS, and iNOS [11].
CONCLUSIONS: The lack of alteration was concluded to be the possible result of cavernosal damage in arteriogenic impotence leading to diminished release of NO and increased release of endothelin [12].

Analytical, diagnostic and therapeutic context of Impotence, Vasculogenic

Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence [13].

References

Radiation-associated impotence. A clinical study of its mechanism. Goldstein, I., Feldman, M.I., Deckers, P.J., Babayan, R.K., Krane, R.J. JAMA (1984) [Pubmed]
Decreased trabecular smooth muscle and caveolin-1 expression in the penile tissue of aged rats. Bakircioglu, M.E., Sievert, K.D., Nunes, L., Lau, A., Lin, C.S., Lue, T.F. J. Urol. (2001) [Pubmed]
Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. Mulhall, J.P., Daller, M., Traish, A.M., Gupta, S., Park, K., Salimpour, P., Payton, T.R., Krane, R.J., Goldstein, I. J. Urol. (1997) [Pubmed]
The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence. Lin, J.S., Lui, S.M., Chen, C.M., Chang, W.C. J. Urol. (1992) [Pubmed]
The diagnosis of venogenic impotence: dynamic or pharmacologic cavernosometry? Stief, C.G., Diederichs, W., Benard, F., Bosch, R., Lue, T.F., Tanagho, E.A. J. Urol. (1988) [Pubmed]
Intracavernous injection of prostaglandin E1 in impotent men. Stackl, W., Hasun, R., Marberger, M. J. Urol. (1988) [Pubmed]
Prostacyclin-to-thromboxane A2 ratio in arteriogenic impotence. Kim, S.C., Choi, I.G., Oh, C.H., Cha, Y.J. J. Urol. (1990) [Pubmed]
Effects of a sclerosant, ethanolamine, on the venous drainage system of the dog penis. Tiong, J.T., Wisniewski, Z.S., Keogh, E.J., Earle, C.M., Tulloch, A.G., Lord, D.J., Harvey, J.M., Papadimitriou, J.M. J. Urol. (1990) [Pubmed]
Prevalence and pathogenesis of impotence in one hundred uremic men. Rodger, R.S., Fletcher, K., Dewar, J.H., Genner, D., McHugh, M., Wilkinson, R., Ward, M.K., Kerr, D.N. Uremia investigation. (1984) [Pubmed]
Vascular endothelial growth factor induces IP-10 chemokine expression. Lin, C.S., Lin, G., Chen, K.C., Ho, H.C., Lue, T.F. Biochem. Biophys. Res. Commun. (2002) [Pubmed]
Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms. Lin, C.S., Ho, H.C., Chen, K.C., Lin, G., Nunes, L., Lue, T.F. BJU international. (2002) [Pubmed]
Intracavernosal endothelin levels of impotent men before and after papaverine induced penile erection. Kadioğlu, A., Memişoğlu, K., Sazoya, O., Tüzün, E. Arch. Esp. Urol. (1998) [Pubmed]
Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence. Kattan, S., Collins, J.P., Mohr, D. Urology (1991) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.